Gene therapy: Therapeutic gene causing lymphoma

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

The development of T-cell leukaemia following the otherwise successful treatment of three patients with X-linked severe combined immune deficiency (X-SCID) in gene-therapy trials using haematopoietic stem cells has led to a re-evaluation of this approach. Using a mouse model for gene therapy of X-SCID, we find that the corrective therapeutic gene IL2RG itself can act as a contributor to the genesis of T-cell lymphomas, with one-third of animals being affected. Gene-therapy trials for X-SCID, which have been based on the assumption that IL2RG is minimally oncogenic, may therefore pose some risk to patients.

Detaljer

Författare
Externa organisationer
  • Salk Institute for Biological Studies
  • Albert-Ludwigs University Freiburg
  • German Cancer Research Centre
Forskningsområden

Nyckelord

Originalspråkengelska
Sidor (från-till)1123
Antal sidor1
TidskriftNature
Volym440
Utgåva nummer7088
StatusPublished - 2006 apr 27
PublikationskategoriForskning
Peer review utfördJa
Externt publiceradJa